{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T16:09:36Z","timestamp":1778256576572,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.medj.2026.101101","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:09:02Z","timestamp":1778252942000},"page":"101101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Building on CD19 based therapy for relapse or refractory follicular lymphoma"],"prefix":"10.1016","volume":"7","author":[{"given":"Khushali","family":"Jhaveri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101101_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(25)01778-7","article-title":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","volume":"407","author":"Sehn","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101101_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101101_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.medj.2026.101101_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2022-158631","article-title":"Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","volume":"140","author":"Leonard","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medj.2026.101101_bib5","first-page":"439","article-title":"Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience","volume":"110","author":"Cassanello","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.medj.2026.101101_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101101_bib7","article-title":"28 | OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED\/REFRACTORY FOLLICULAR LYMPHOMA (R\/R FL)","volume":"43","author":"Sehn","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101101_bib8","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/j.jtct.2025.12.538","article-title":"Activity of Autologous Anti-CD19 Chimeric Antigen Receptor T-cell Therapy in CD19-Negative Large B-cell Lymphoma: A Cell Therapy Consortium Real World Experience","volume":"32","author":"Zhang","year":"2026","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.medj.2026.101101_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101101_bib10","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:11:04Z","timestamp":1778253064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666634026001042"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101101","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Building on CD19 based therapy for relapse or refractory follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101101"}}